Bioavailability of indomethacin-saccharin cocrystals

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 11, 2010, Pages 1560-1568

  Jung, Min Sook ^a   Kim, Jeong Soo ^a   Kim, Min Soo ^a   Alhalaweh, Amjad ^b   Cho, Wonkyung ^a   Hwang, Sung Joo ^a   Velaga, Sitaram P ^b  

^a Chungnam National University   (South Korea)

^b LULEÅ UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

bioavailability; cocrystals; dissolution; indomethacin; salts

Indexed keywords

GELATIN; INDOMETACIN; NANOCRYSTAL; SACCHARIN;

ANALYSIS OF VARIANCE; ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PH; PHYSICAL CHEMISTRY; SCALE UP; SCANNING ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

ANIMALS; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DOGS; INDOMETHACIN; LACTOSE; SACCHARIN; SOLUBILITY;

EID: 78649678462     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01189.x     Document Type: Article

References (34)

1. Amidon GL, et al. A theoretical basis for a biopharmaceutic drug classification-the correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res 1995; 12: 413-420.
2. Singhal D, Curatolo W,. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev 2004; 56: 335-347.
3. Dhumal R, et al. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability. J Pharm Pharmacol 2009; 61: 743-751.
4. Monissette SL, et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 2004; 56: 275-300.
5. Berge SM, et al. Pharmaceutical salts. J Pharm Sci 1977; 66: 1-19.
6. Morissette SL, et al. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc Natl Acad Sci USA 2003; 100: 2180-2184.
7. Heinz A, et al. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol 2009; 61: 971-988.
8. Vishweshwar P, et al. Pharmaceutical co-crystals. J Pharm Sci 2006; 95: 499-516.
9. Jones W, et al. Pharmaceutical cocrystals: an emerging approach to physical property enhancement. MRS Bull 2006; 31: 875-879.
10. Schultheiss N, Newman A,. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 2009; 9: 2950-2967.
11. Aakeroy CB, Salmon DJ,. Building co-crystals with molecular sense and supramolecular sensibility. Cryst Eng Comm 2005; 7: 439-448.
12. Zaworotko M,. Pharmaceutical co-crystals: do they represent a new path to improved medicines? J Pharm Pharmacol 2006; 58: A91-A91.
13. Bond AB,. What is a co-crystal? Cryst Eng Comm 2007; 9: 833-834.
14. Childs SL, Hardcastle KI,. Cocrystals of piroxicam with carboxylic acids. Cryst Growth Des 2007; 7: 1291-1304.
15. Basavoju S, et al. Pharmaceutical cocrystal and salts of norfloxacin. Cryst Growth Des 2006; 6: 2699-2708.
16. McNamara DP, et al. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 2006; 23: 1888-1897.
17. Bak A, et al. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci 2008; 97: 3942-3956.
18. Hickey MB, et al. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm 2007; 67: 112-119.
19. Yazdanian M, et al. The 'high solubility' definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 2004; 21: 293-299.
20. Matsumoto T, Zografi G,. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm Res 1999; 16: 1722-1728.
21. Habib MJ, et al. Improved dissolution of indomethacin in coprecipitates with phospholipids.1. Drug Dev Ind Pharm 1993; 19: 499-505.
22. Wulff M, Alden M,. Solid state studies of drug-cyclodextrin inclusion complexes in PEG 6000 prepared by a new method. Eur J Pharm Sci 1999; 8: 269-281.
23. Basavoju S, et al. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res 2008; 25: 530-541.
24. Velaga SP, et al. Investigation of pH dependent solubility and stability of a cocrystal with ionizable acidic components. AAPS Meet Expos [online] 2009; (accessed 17 September 2010).
25. Velaga SP, et al. Models that explain the solubility behaviour of Indomethacin-Saccharin cocrystal in organic media. AAPS Meet Expos [online] 2009; (accessed 17 September 2010).
26. Nam HG, et al. Effect of skin penetration enhancer on the drug release from indomethacin-soft hydrogel. J Korean Pharm Sci 2002; 32: 35-40.
27. Gagniere E, et al. Formation of co-crystals: kinetic and thermodynamic aspects. J Cryst Growth 2009; 311: 2689-2695.
28. Gagniere E, et al. Cocrystal formation in solution: in situ solute concentration monitoring of the two components and kinetic pathways. Cryst Growth Des 2009; 9: 3376-3383.
29. Shiraki K, et al. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res 2008; 25: 2581-2592.
30. Aoyagi N, et al. Gastric-emptying of tablets and granules in humans, dogs, pigs, and stomach-emptying-controlled rabbits. J Pharm Sci 1992; 81: 1170-1174.
31. Aoyagi N, et al. Bioavailability of indomethacin capsules in humans. III: correlation with bioavailability in beagle dogs. Int J Clin Pharmacol 1985; 23: 578-584. (Pubitemid 16250295)
32. Hosny EA, et al. Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. Pharm Acta Helv 1997; 72: 159-164.
33. Bethune SJ, et al. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst Growth Des 2009; 9: 3976-3988.
34. Remenar JF, et al. Celecoxib: nicotinamide dissociation: using excipients to capture the cocrystal's potential. Mol Pharm 2007; 4: 386-400.